Savant Capital LLC Acquires New Position in Insmed, Inc. $INSM

Savant Capital LLC bought a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,036 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ORG Partners LLC grew its stake in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares during the period. Hilltop National Bank acquired a new position in Insmed in the second quarter valued at approximately $28,000. FNY Investment Advisers LLC acquired a new position in Insmed in the second quarter valued at approximately $33,000. LRI Investments LLC purchased a new position in Insmed in the second quarter worth approximately $59,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in Insmed during the first quarter worth $79,000.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. UBS Group upped their price target on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Truist Financial boosted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Evercore ISI reaffirmed an “outperform” rating and issued a $180.00 target price on shares of Insmed in a research report on Wednesday, October 1st. Wells Fargo & Company increased their target price on shares of Insmed from $171.00 to $217.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Jefferies Financial Group lifted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average target price of $175.53.

Insmed Price Performance

INSM opened at $199.64 on Friday. The stock’s 50-day moving average price is $166.68 and its 200 day moving average price is $123.91. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $208.00. The firm has a market cap of $42.58 billion, a price-to-earnings ratio of -34.96 and a beta of 1.05. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the transaction, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. This trade represents a 13.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Leo Lee sold 75,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the completion of the transaction, the director owned 54,677 shares of the company’s stock, valued at approximately $10,711,224.30. This trade represents a 57.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 252,922 shares of company stock valued at $43,533,383. 3.00% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.